The proof of concept of our O-IL8-15 therapeutic serves as a foundation for a new mRNA-based treatment platform and further research in synthetic biology. Considering our promising results (see Results), future research will focus on finding new targets, optimising the mRNA design and stability of scFv proteins, and further research into nanobodies. (see Experimental Outlook on the Results page). The therapeutic should now be tested in vivo, through animal and clinical trials, to confirm the effects there. Next to optimizing the proof of concept, the technology should be patented to protect the IP for future business opportunities (see Entrepreneurship).
MetraMorpheus is currently designed for Endometriosis, however, the modularity of the mRNA-based platform offers great potential for this treatment to be applicable to multiple diseases at a very low cost.